SOURCE: BioProgress PLC

January 23, 2007 02:01 ET

BioProgress PLC - Product Update

Cambridgeshire -- (MARKET WIRE) -- January 23, 2007 --

For Immediate Release                                    23 January 2007

                           BioProgress plc

                       Product Development Update

London, UK, 23 January 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company, announces that it has successfully achieved indicative stability for its DBP117 Migraine treatment product using its propriety Soluleaves™ technology. It has also developed the patented nicotine DBP121 thin strip product, which will shortly be entering stability for the smoking cessation market. Both products are designed to undergo rapid development and commercialisation.

Both proprietary developed products use established molecules and are the first in a series of product developments incorporating potent pharmaceutical products. The work undertaken so far by the dedicated team at BioProgress has been able to generate the high level of manufacturing standards required to register a potent drug in a melt-in-a-mouth film.

Both product developments represent novel forms of pharmaceuticals with rapid and sustained release characteristics. The potential market for DBP117 is valued at $3.3 billion (Datamonitor 2006). The nicotine replacement market was over GBP88m in the UK alone in 2005. In both cases the products are global and possess unique intellectual property enabling marketing on a worldwide basis.

Steve Martin, Chief Development Officer said:

"We are in discussions on these exciting and novel product forms of pharmaceuticals with a number of potential licensing partners, including global top10 pharmaceutical companies."

For further information:

BioProgress Plc                        + 44 (0) 20 7098 9881

Richard Trevillion, CEO

Steve Martin, CDO

Buchanan Communications                + 44 (0) 20 7466 5000

Rebecca Skye Dietrich / Mark Court

About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™ polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

                      This information is provided by RNS
            The company news service from the London Stock Exchange